Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry

Canadian Journal of Cardiology

Volumn 25, Issue 11, 2009, Pages 625-630

  Warren, Andrew E ^a   Hamilton, R M ^b   Belanger S A ^c   Gray, C ^d   Gow, R M ^d   Sanatani, S ^e   Cote J M ^f   Lougheed, J ^d   LeBlanc, J ^a   Martin, S ^g   Miles, B ^h   Mitchell, C ⁱ   Gorman, D A ^b   Weiss, M ^e   Schachar, R ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g Royal Alexandra Hospital   (Canada)

^h Dufferin Peel Catholic District School Board   (Canada)

ⁱ Ministry of Children and Youth Services Child and Parent Resource Institute   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Consensus statement; Pediatric; Population health; Risk; Sudden death

Indexed keywords

CENTRAL STIMULANT AGENT;

ANAMNESIS; ATTENTION DEFICIT DISORDER; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONGENITAL HEART DISEASE; CONSULTATION; DRUG SAFETY; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNET; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDICAL SPECIALIST; PEER REVIEW; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SUDDEN DEATH; UNITED STATES;

ADOLESCENT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CANADA; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; RISK ASSESSMENT; SEX FACTORS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 70549085037     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70157-6     Document Type: Article

References (39)

1. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279:1100-1107.
2. American Academy of Pediatrics, Subcommittee of Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:1033-1044.
3. Health Canada. Updating of Product Monograph of Attention Deficit Hyperactivity Disorder (ADHD) Drugs - For Health Professionals. 〈http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/-2006/ adhd-tdah-medic-hpc-cps-eng.php〉 (Version current at August 10, 2009).
4. US Food and Drug Administration, Drug Safety and Risk Management Advisory Committee. 〈www.fda.gov/oc/advisory/accalendar/2006/cder12535dd02091006. html〉 (Version current at August 10, 2009).
5. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-2423. (Pubitemid 351653546)
6. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451-453.
7. American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008;29:335.
8. Conway J, Wong KK, O'Connell C, Warren AE. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: Impact of the Health Canada advisory. Pediatrics 2008;122:e828-34.
9. Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd edn. New York: Guilford Publications Inc, 1998:197.
10. Slomkowski C, Klein RG, Mannuzza S. Is self-esteem an important outcome in hyperactive children? J Abnorm Child Psychol 1995;23:303-315.
11. Brown RT, Pacini JN. Perceived family functioning, marital status, and depression in parents of boys with attention deficit disorder. J Learn Disabil 1989;22:581-587.
12. Stein MA, Szumowski E, Blondis TA, Roizen NJ. Adaptive skills dysfunction in ADD and ADHD children. J Child Psychol Psychiatry 1995;36:663-670.
13. Greenhill LL. Diagnosing attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 1998;59(Suppl 7):31-41.
14. Biederman J, Wilens T, Mick E, Spencer T, Faraone V. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104:e20.
15. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996;98:1089-1095. (Pubitemid 26399271)
16. Shillingford AJ, Glanzman MM, Ittenbach RF, Clancy RR, Gaynor JW, Wernovsky G. Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 2008;121:e759-67.
17. Hovels-Gurich HH, Konrad K, Skorzenski D, et al. Long term neurodevelopmental outcomes and exercise capacity after corrective surgery for tetralogy of Fallot or VSD in infancy. Ann Thorac Surg 2006;83:958-966. (Pubitemid 43247667)
18. Wren C, O'Sullivan JJ, Wright C. Sudden death in children and adolescents. Heart 2000;83:410-413.
19. Berger S, Utech L, Hazinski MF. Sudden death in children and adolescents. Pediatr Clin North Am 2004;51:1653-1677.
20. Rappley MD, Moore JW, Dokken D. ADHD drugs and cardiovascular risk. N Eng J Med 2006;354:2296-2298.
21. Neuspiel DR, Kuller LH. Sudden and unexpected natural death in childhood and adolescence. JAMA 1985;254:1321-1325. (Pubitemid 15236604)
22. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Eng J Med 1998;339:364-369. (Pubitemid 28363798)
23. Berger S, Kugler JD, Thomas JA, Friedberg DZ. Sudden cardiac death in children and adolescents: Introduction and overview. Pediatr Clin North Am 2004;51:1201-1209.
24. Bar-Cohen Y, Silka MJ. Sudden cardiac death in pediatrics. Curr Opin Pediatr 2008;20:517-521.
25. Wisten A, Messner T. Symptoms preceding sudden cardiac death in the young are common but often misinterpreted. Scand Cardiovasc J 2005;39:143-149. (Pubitemid 41657524)
26. Silka M, Hardy B, Menashe V, Morris C. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. JACC 1998;32:245-251. (Pubitemid 28351069)
27. Nieminen H, Jokinen E, Sairanen H. Causes of late deaths after pediatric surgery: A population based study. J Am Coll Cardiol 2007;50:1263-1271. (Pubitemid 47405126)
28. Sanatani S, Wilson G, Smith CR, Hamilton RM, Williams WG, Adatia I. Sudden unexpected death in children with heart disease. Congenit Heart Dis 2006;1:89-97.
29. Dancea A, Côté A, Rohlicek C, Bernard C, Oligny LL. Cardiac pathology in sudden unexpected infant death. J Pediatr 2002;141:336-342. (Pubitemid 35041922)
30. Winterstein G, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007;120:e1494-501. (Pubitemid 350223669)
31. Gelperin K, Benoit S, Pamer C. Review of AERS data for marketed safety experience during stimulant therapy: Death, sudden death, cardiovascular SAEs (including stroke). 〈http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006- 4202B1-05-FDA-Tab05.pdf〉 (Version current at August 10, 2009).
32. Racoosin J. Follow up review of AERS search identifying cases of sudden death occurring with drugs used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). 〈http://www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4210b-07-01-safetyreview.pdf〉 (Version current at August 10, 2009).
33. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009;166:992-1001.
34. The U.S. Food and Drug Administration. Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD). 〈http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm〉 (Version current at August 10, 2009).
35. Campbell RM, Berger S. Preventing pediatric sudden cardiac death: Where do we start? Pediatrics 2006;118;802-804.
36. Fuller C. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 2000;32:887-890. (Pubitemid 30230667)
37. Tanaka Y, Yoshinaga M, Anan R, et al. Usefulness and cost effectiveness of cardiovascular screening of young adolescents. Med Sci Sports Exerc 2006;38:2-6.
38. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006;296:1593-1601. (Pubitemid 44515020)
39. Frohna JG. A preparticipation sreening program can decrease the incidence of sudden cardiac death among young athletes. J Pediatr 2007;150:319-320.